Adial Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 2834 www.adial.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans - Mar 24th, 2026 7:07 am
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - Mar 6th, 2026 6:00 am
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement - Mar 3rd, 2026 6:17 am
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Feb 24th, 2026 7:00 am
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - Feb 23rd, 2026 6:30 am
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 17th, 2026 7:00 am
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 - Feb 4th, 2026 7:35 am
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement - Feb 3rd, 2026 2:05 pm
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 - Jan 14th, 2026 7:00 am
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Jan 6th, 2026 7:40 am
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds - Nov 26th, 2025 6:00 am
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 14th, 2025 6:30 am
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - Oct 17th, 2025 7:00 am
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution - Oct 9th, 2025 6:30 am
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls - Sep 30th, 2025 7:42 am
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder - Sep 16th, 2025 6:03 am
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 - Sep 16th, 2025 6:00 am
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule - Sep 3rd, 2025 6:30 am
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy - Sep 1st, 2025 10:00 am
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments - Aug 20th, 2025 6:30 am